Future validation of our work could be performed by constructing breast cancer cell lines overexpressing DNA helicases BLM, FIGNL1, PIF1, or FBXOI8 and cell lines downregulating HELQ. Efficiency of HRR in the constructed cell lines should be evaluated by assays including H2Agamma foci quantification. The gene discussed is BLM; the disease is breast cancer.